课题基金 / 基金详情

HIV Persistence and Cardiopulmonary Disease

HIV Persistence and Cardiopulmonary Disease
艾滋病毒持续存在与心肺疾病
批准号:
9098781
负责人:
Maria S. Salvato
金额:
$23.1万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2018-04-30

项目摘要

项目成果

Maria S. Salvato的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is increased more than 10-times in patients with HIV compared to the general population. Endothelial cell proliferation driven by chronic inflammation restricts blood flow arteries and increases right hear pressures. PAH is also seen in SHIV-infected macaques and was confirmed by necropsy findings of intimal thickening in the pulmonary vasculature. One new approach to PAH treatment uses the CCR5-blocking drug Maraviroc that was therapeutic in SHIV+ animals (Kelly, et. al, 2014). This finding supports a view that PAH is driven by chronic inflammation but does not explain the reasons for increased PAH in patients with HIV. We postulate that HIV-mediated depletion and dysregulation of T cells impairs a critical mechanism for the control of chrnic inflammation. Normally,  T cells provide costimulation to NK that increases their potency s cytotoxic effectors against dendritic cells (DC). In the absence of normal  T cell functio, NK do not receive critical costimulation, their capacity for eliminating DC is lost and with it, contrl of inflammation is impaired. Our strategy for treating PAH is to use two clinically approved drugs, zoledronic acid and IL2, that together will activate and expand the costimulatory  T cells By restoring normal  T cells function, we reconstitute the capacity for NK costimulation, DC killing and control of inflammation. Because of high PAH incidence and a proven therapeutic effect of Maraviroc, the SHIV-infected macaque is an ideal model for testing new therapeutic strategies including the direct activation of  T cells to resolve chronic inflammation. Mutiple co-morbid conditions of HIV disease are believed to be related to an underlying chronic immune activation and inflammation. By developing a therapeutic intervention against PAH, we may identify a strategy that is generally useful for blocking chronic inflammation that will improve an extend the lives of patients with HIV.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
FcRn-targeted mucosal HIV vaccine
  • 批准号:
    8880111
  • 项目类别:
  • 资助金额:
    $74.7万
  • 财政年份:
    2012
  • 负责人:
    Maria S. Salvato
  • 依托单位:
Protection of vaccine immunity by inhibiting Fas/FasL signaling
  • 批准号:
    7944104
  • 项目类别:
  • 资助金额:
    $49.21万
  • 财政年份:
    2009
  • 负责人:
    Maria S. Salvato
  • 依托单位:
A Lassa Vaccine in primates with AIDS
  • 批准号:
    7914705
  • 项目类别:
  • 资助金额:
    $7.5万
  • 财政年份:
    2009
  • 负责人:
    Maria S. Salvato
  • 依托单位:
Protection of vaccine immunity by inhibiting Fas/FasL signaling
  • 批准号:
    7853033
  • 项目类别:
  • 资助金额:
    $49.28万
  • 财政年份:
    2009
  • 负责人:
    Maria S. Salvato
  • 依托单位:
海外基金